A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation. Clinical study No. MGL-3196-11.

Project: Research

StatusActive
Effective start/end date24/10/1931/12/24

Keywords

  • Hepatology
  • Cirrhosis
  • Clinical trial